Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT01471613

Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury

Safety and Effect of Lithium, Umbilical Cord Blood Cells and the Combination in the Treatment of Acute and Sub-acute Spinal Cord Injury : a Randomized, Double-Blinded Placebo-Controlled Clinical Trial

Sponsor: Chengdu PLA General Hospital

Conditions Spinal Cord Injury

Interventions Conventional Treatment Cord Blood Cell Lithium Carbonate Tablet Placebo

Updated 5 times since 2017 Last updated: Jan 27, 2014 Started: Sep 30, 2011 Primary completion: Dec 31, 2013 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01471613, this PHASE1/PHASE2 trial focuses on Spinal Cord Injury and remains completed. Sponsored by Chengdu PLA General Hospital, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chengdu PLA General Hospital
China Spinal Cord Injury Network
StemCyte, Inc.

Data source: China Spinal Cord Injury Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kunming, China